Bayer Puts a Brighter Debt Picture on the Table, But the Legal Clock Still Ticks Toward September

Bayer beats Q2 expectations, trims net debt guidance to €29-30B after Apollo's €3B LARC stake, while glyphosate settlement hearing moves to Sept 14.

The chemistry between balance-sheet repair and courtroom calendar management is rarely this visible. For Bayer, the second quarter of 2026 delivered both: a sharper-than-expected reduction in net debt guidance and a rescheduled hearing in the long-running glyphosate litigation that pushes the final word on a multibillion-dollar settlement deeper into the autumn.

The centerpiece of the debt improvement is a 3.0 billion euro infusion from private equity firm Apollo, which is taking a non-controlling minority stake in Bayer's long-acting reversible contraception (LARC) business. The transaction, expected to close in the third quarter of 2026 and still subject to antitrust clearance, leaves Bayer with both the majority ownership and full operational control. Management has already folded the expected proceeds into its full-year outlook, trimming the net financial debt forecast to 29–30 billion euros from the previously communicated 32–33 billion euros.

Crop Science Carries the Quarter

The more favorable leverage picture rests on a solid operational base. Group revenue rose 2.2 percent on a currency- and portfolio-adjusted basis to 10.9 billion euros in the April-to-June period, with the agricultural division Crop Science doing the heavy lifting. Adjusted EBITDA advanced 1.9 percent to 2.1 billion euros, while the division's adjusted earnings jumped 30.2 percent. Perhaps most tellingly, Bayer swung back to profitability with a net profit of 219 million euros, reversing a 199 million euro loss in the same quarter a year earlier.

Not every metric pointed in the same direction. Core earnings per share slipped 16.7 percent to 0.95 euros, weighed down by higher tax charges and softer results in select segments. Still, management held its full-year guidance steady: adjusted EBITDA of 9.6–10.1 billion euros, core EPS of 4.30–4.90 euros, and group sales of 44.7–47.0 billion euros at constant currencies. The slightly different EPS corridor of 4.10–4.80 euros cited in the company's outlook reflects the same underlying target range. Several analysts raised their price targets following the release.

A Market That's Paying Attention to the Balance Sheet

Investors have taken notice. The shares now trade at 49.06 euros, up 72 percent over the past twelve months and roughly 19 percent above the 200-day moving average of 41.11 euros. The most recent 30-day stretch shows a 3.7 percent gain, suggesting the market is currently weighing the deleveraging story more heavily than the unresolved legal overhang.

That overhang, however, is not going away. A US court has pushed back the hearing on the proposed glyphosate class settlement — originally set for August 19 — to September 14. Both Bayer and the plaintiffs jointly requested the delay, initially asking for September 10 or later, to allow time to process a backlog of opt-out revocation requests that arrived in the wake of a Supreme Court decision. Final approval of the settlement, announced in February and valued at up to 7.25 billion US dollars, is still expected before the end of the year.

More Than Just Debt and Litigation

Beyond the balance sheet and the courtroom, Bayer has been quietly advancing its pharmaceutical pipeline. The completion of the Perfuse Therapeutics acquisition in June brought full rights to PER-001, a Phase II intravitreal implant candidate for glaucoma and diabetic retinopathy. The deal, unveiled in May, carries an upfront payment of 300 million US dollars, with the total package potentially reaching 2.45 billion US dollars depending on the candidate's success.

There has also been a change in the finance function: Judith Hartmann took over as chief financial officer in June, succeeding Wolfgang Nickl, who retired.

What emerges is a company running two parallel tracks — one defined by operational stabilization, targeted deleveraging, and pipeline expansion, the other by a legal process whose resolution date keeps sliding. The September 14 hearing provides a concrete marker, but whether it brings closure or further delay remains the open question for investors.